AGP Executive Report

Ebola Alert: Macau’s Health Bureau (SSM) is urging residents and private clinics to step up vigilance after WHO declared the Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern, with new checks at border points, hospitals and the community, and infection-control briefings for frontline staff. Inclusion & Mental Health: The 5-day Inclusion Conference & Festival is underway, with free talks, parent-expert consultations, and neurodiversity support sessions at MGM COTAI, drawing 300+ participants and focusing on practical inclusion strategies. Children’s Rights: International Children’s Day events kick off across Macau under a theme of children’s participation rights, with performances and interactive activities planned citywide. Cross-border Health Tech (context): Hong Kong is pushing a simpler eHealth app “Lite Mode” to close the senior digital gap, while Macau’s own health support continues to expand through vouchers and cross-boundary access.

Cross-border care push (Hong Kong): Bupa Hong Kong launched “Bupa Care Bridge,” an affordable plan built for people who split life between Hong Kong and Mainland China, with inpatient coverage across both and outpatient/preventive care anchored in Hong Kong. Digital health for seniors (Hong Kong): The eHealth app is getting a simpler “Lite Mode” and easier features, after only 46% of registered seniors had activated the app—plus community support stations and home visits to boost uptake. Faster drug access (Hong Kong): Hong Kong’s new medical watchdog setup is expected to let mainland innovative drugmakers apply for SAR registration while also using National Medical Products Administration registration, aiming to speed market entry. Macau public health & policy: Macau is trialing a three-sided open-air smoking booth as smoke-free zones expand, while the Health Bureau continues monitoring a hantavirus situation tied to an Atlantic cruise ship. Drug pipeline momentum (region): Vincentage Pharma reported positive Phase 3 top-line results for VCT220 in overweight/obese Chinese adults, and Fosun Pharma and AriBio signed an exclusive global option deal for Alzheimer’s candidate AR1001.

Hantavirus Alert: Macau’s Health Bureau (SSM) is urging travellers—especially those heading to South America—to stay vigilant after WHO-linked cases tied to an Atlantic cruise ship, with Andes virus reported and limited person-to-person spread possible only with prolonged close contact. Inclusion Focus: The INCLUSION Conference & Festival starts today, with free talks and a “Macau Golf Masters” run, centring evidence-based support for neurodiverse people and families, including mental health and suicide prevention themes. Community Health Access: SSM has also highlighted progress on hypertension care—about 89% of registered patients received treatment last year—alongside wider blood-pressure check points across Macau. Cross-border Support: Social Security Fund outreach in Hengqin promotes new convenience measures under Law No. 3/2026, including how time spent in the Cooperation Zone can count toward Macau social security coverage. Health Policy in Motion: The week also saw continued rollout of Macau health e-vouchers and medical subsidy updates extending eligible use into Guangdong.

Digital Health & Access: Hong Kong rolled out an updated eHealth app interface with personalised dashboards, easier record viewing, and better cross-boundary health record requests—aimed at making digital care management more user-friendly. Macao Health Support: Macau’s MOP700 medical vouchers stay in place for 2026, with use expanding to eligible Guangdong clinics and outpatient departments starting next month via “Macao One Account.” Public Health Watch: Macau confirmed its first imported malaria case of the year in a 47-year-old man who travelled to Nigeria; he remains hospitalised in serious condition. Local Services & Economy: O MEDIA launched “Access Macau” to help international firms enter the SAR market, tied to concessionaires’ non-gaming investment commitments. Macao Community Life: The “Happy Family Month” expands into Hengqin under a new 6+1 regional network, with hundreds of events planned. Hypertension Progress: Macau’s Health Bureau reported about 89% of registered hypertension patients received treatment last year.

Cross-border social security: Macau’s Social Security Fund held community briefings in Hengqin to roll out the revised two-tier social security rules, including a key change that time spent in the Cooperation Zone counts as time in Macau, with about 480 residents attending. Health access in Guangdong: Macau’s health e-vouchers stay at MOP700 for 2026 and can be used in eligible Guangdong clinics/outpatient departments starting June 1 via “Macao One Account,” extending cross-border convenience for permanent residents. Public health watch: Macau confirmed its first imported malaria case of the year—an adult man who traveled to Nigeria and is in serious condition after diagnosis with Plasmodium falciparum. Macao-Hengqin MICE push: Macau and Hengqin won awards for annual meetings and innovative MICE policy support, backing the “multi-venue event” model. Big pharma deal with local relevance: BMS and Hengrui signed a global pact worth up to $15.2B for 13 early-stage oncology/immunology programs, underscoring how China-linked R&D is reshaping global drug pipelines.

BMS–Hengrui Deal: Bristol Myers Squibb and China’s Hengrui Pharma signed a global collaboration and licensing pact worth up to $15.2 billion, covering 13 early-stage oncology, hematology and immunology programs, with Hengrui leading early clinical development and both sides splitting rights by territory; the deal is expected to close in Q3 2026. Macao Health Access: Macau’s MOP700 medical e-vouchers are set to expand into Guangdong clinics/outpatient departments from June 1, while the Health Bureau reported Macao’s first imported malaria case of the year (a mainland man returning from Nigeria, in serious condition). Chronic Disease Focus: The Health Bureau says about 89% of registered hypertension patients received treatment in 2024, supported by 337 blood-pressure check points. Cross-border Convenience: The Social Security Fund held briefings in Hengqin on the revised two-tier social security law, aiming to make cross-border benefits feel “without distance.” Local Public Health Watch: Macau also reported a Legionnaires’ disease case involving an 83-year-old resident, bringing the year’s total to six.

Cross-border health access: Macau’s MOP700 health e-vouchers stay the same for 2026, but use is set to expand into Guangdong clinics and outpatient departments starting next month via “Macao One Account.” Disease watch: Macau confirmed its first imported malaria case of the year—an adult man who traveled to Nigeria and is in serious condition in hospital. Chronic disease progress: The Health Bureau says about 89% of registered hypertension patients received treatment in 2024, with measurement points now at 337 locations across the city. Regional health services: Social Security Fund briefings in Hengqin rolled out new cross-border convenience under revised Macau social security rules, including time spent in Hengqin counting toward Macau. Big pharma momentum: Bristol Myers Squibb and Hengrui signed a deal worth up to US$15.2B for 13 early-stage oncology/hematology/immunology programs—another sign Macau’s wider Greater Bay Area health ecosystem keeps pulling in global capital.

Cross-border Social Security: Macau’s Social Security Fund held two Hengqin briefings for residents in the Cooperation Zone, rolling out the new Law No. 3/2026 that counts time spent in Hengqin as time in Macau, with about 480 people attending. Local Health Access: The Health Bureau says 89% of registered hypertension patients were receiving treatment in 2024, alongside 337 blood-pressure check points across the city. Macau Medical Vouchers Expand: The MOP700 health e-vouchers keep the same amount for 2026, but from next month they can be used at eligible clinics in Guangdong, via “Macao One Account.” Infectious Disease Watch: Macau confirmed its first imported malaria case this year, a 47-year-old man hospitalized after travel to Nigeria. Big Pharma Deal: Outside Macau, Bristol Myers Squibb and Hengrui signed a potential $15.2B collaboration covering 13 early oncology/immunology programs.

Hypertension Care Update: Macau’s Health Bureau says 89% of registered hypertension patients are receiving treatment, with 62.6% reaching control—alongside 337 blood-pressure measurement points across the city. Cross-Border Health Support: The MOP700 medical e-voucher scheme is set to keep the same value for 2026 and expand use to eligible Guangdong clinics starting next month, with vouchers also usable via “Macao One Account.” Infectious Disease Watch: Macau confirmed its first imported malaria case of the year—an adult man returning from Nigeria—while authorities continue hospital monitoring. Big Pharma Deal (Regional Impact): Bristol Myers Squibb and Hengrui Pharma signed a collaboration worth up to $15.2B for 13 early-stage oncology, hematology, and immunology programs, with Hengrui leading early development. Clinical Progress: EyePoint reported a DSMC recommendation to keep its DURAVYU wet AMD Phase 3 trials on track, citing continued favorable safety.

Biopharma Dealmaking: Fosun Pharma is doubling down on Alzheimer’s by signing an exclusive global option with AriBio for AR1001, with Fosun set to pay up to USD240M more for rights in major markets like the US and Europe, after already securing China/HK/Macao and parts of ASEAN. Oncology Target Rush: A once “untouchable” cancer antigen, B7-H3, is suddenly crowded with new programs, including a fresh NK-cell engager entering Phase 1—showing how fast oncology target strategies are shifting. Ophthalmology Confidence Check: EyePoint says an independent DSMC gave a third straight positive recommendation for its Phase 3 wet AMD trials of DURAVYU, with topline data still aimed for mid-2026. Macao Health Access: The MOP700 medical e-voucher scheme stays at the same level and will expand use to Guangdong clinics starting next month, while Macau also confirmed its first imported malaria case this year. Local Life & Health Culture: More than 20 museums will kick off the Macao International Museum Day Carnival 2026 at Lotus Square on Sunday.

Imported Malaria Alert: Macau confirmed its first imported malaria case of the year—a 47-year-old man who traveled to Nigeria, developed fever and diarrhoea after returning, and is now hospitalised in serious condition. Cross-Border Care: Macau’s health e-vouchers (700 patacas) are set to work in Guangdong again starting June 1, extending access for eligible residents for two years. Big-Health Dealmaking: Bristol Myers Squibb and Hengrui Pharma signed a collaboration worth up to $15.2B to co-develop 13 early-stage oncology, hematology and immunology programs—relevant to Macau through Hengrui’s Greater China rights. Infection Watch: Macau also reported a sharp April mosquito breeding uptick, raising dengue and chikungunya risk, while a separate Legionnaires’ disease case brought the year’s total to six. Regional Health Hubs: Hong Kong’s embodied AI summit and International Healthcare Week opened this week, pushing AI and innovation into real-world healthcare deployment.

Big Pharma Deal: Bristol Myers Squibb and China’s Hengrui Pharma just signed a global collaboration worth up to US$15.2 billion, covering 13 early-stage oncology, hematology, and immunology programs; BMS pays US$600M upfront plus milestone payments, with the deal expected to close in Q3 2026. Local Health Alert: Macau reported a new Legionnaires’ disease case—an 83-year-old man in serious condition after pneumonia and ICU treatment—bringing this year’s total to six. Mosquito Watch: The Health Bureau warned Macau’s mosquito breeding index jumped in April, raising dengue and chikungunya risk. Macau Mobility: Bus ridership hit a seven-year high in Q1, averaging 673,400 trips per day as visitor numbers stay strong. Gaming & Diversification: At G2E Asia, casino executives highlighted Macau’s push toward more suites and continued non-gaming growth, while Galaxy and Sands reported steady momentum.

Biotech Deal Shock: Bristol Myers Squibb and China’s Hengrui Pharma just announced a global collaboration worth up to $15.2B, covering 13 early-stage oncology, hematology, and immunology programs—BMS pays $600M upfront and more in milestones as the partners race to build new pipelines ahead of major patent expiries. Macau Health Alert: The Health Bureau (SSM) reported a serious Legionnaires’ disease case in an 83-year-old man, now in ICU, pushing this year’s total to six. Mosquito & Dengue Risk: SSM warned Macau’s mosquito breeding index jumped in April, raising dengue and chikungunya risk as travel and weather fuel Aedes growth. Local Prevention Push: Govt says it will provide mosquito repellents at 12 parks and rest areas. Healthcare Spotlight: International Healthcare Week opens in Hong Kong, spotlighting healthcare breakthroughs and smart health tech. Gaming Diversification: At G2E Asia, MGM’s Kenneth Feng said Macau suite products can yield up to 5x the revenue of a regular room, as operators rebalance high-end offerings.

Biotech Deal Shock: Jiangsu Hengrui and Bristol Myers Squibb just signed a global collaboration and licensing pact worth up to US$15.2 billion, covering 13 early-stage oncology, hematology and immunology programs; BMS pays US$600m upfront plus anniversary and milestone payments, with closing expected in Q3 2026. Macau Health Watch: The Health Bureau (SSM) says Macau’s mosquito ovitrap index jumped in April, pushing dengue and chikungunya risk higher as temperatures and rainfall accelerate Aedes breeding; authorities are also rolling out free mosquito repellents at government “Health Fuel Stations” and running a two-week stagnant-water cleanup push. Local Governance & Safety: Macau reported another 18 contraband smuggling attempts at the border and airport, while a separate stabbing incident left a 22-year-old under medical care. City Pulse: Galaxy Entertainment posted Q1 2026 results with net revenue up 11% year-on-year, but noted luck effects in quarterly comparisons.

Big Pharma Deal: Jiangsu Hengrui and Bristol Myers Squibb signed global collaboration and licensing deals worth up to $15.2 billion, covering 13 early-stage cancer and blood-disease programmes; BMS gets worldwide rights outside mainland China, Hong Kong and Macau, while Hengrui takes exclusive rights in those markets. AI in Everyday Life: China’s rapid AI adoption is moving from hype to mass use, with people lining up for help setting up AI “agents” on their laptops—showing how quickly tools are becoming workplace and daily-life infrastructure. Macau Health & Prevention: Macau launched a shared mosquito repellent scheme at 12 “Health Fuel Stations” in parks and rest areas, alongside a two-week push to eliminate stagnant water to curb dengue and chikungunya. Local Governance: Chief Executive Sam Hou Fai urged Macau’s community organisations to strengthen grassroots governance, expand social services for vulnerable groups, and support law-based governance. SME Trade Push: Guangdong-Macao Branded Products Fair exhibitor recruitment opened for the “Macao Featured Products Zone,” with applications due May 26. Oncology Updates: Erasca reported Q1 2026 business and finances, highlighting progress in its RAS-targeted pipeline.

Hong Kong medical research push: A mainland health official urged Hong Kong to expand its role in major national clinical research and breakthroughs, backing local scientists to join both clinical studies and “basic research” projects, while the Hospital Authority also flagged smarter service pathways and smart-hospital initiatives. Macau dengue prevention gets practical: Macau’s Health Bureau launched a shared mosquito-repellent scheme, with free repellents available at 12 “Health Fuel Stations” in parks and rest areas plus a two-week door-to-door campaign to eliminate stagnant water—aimed at reducing dengue and chikungunya risk. Regional health-and-business momentum: Hong Kong also leaned on its “unrivalled” medical innovation hub status in pandemic preparedness talks, while Macau’s Guangdong & Macao Branded Products Fair (Aug 6–9) opened exhibitor recruitment for a “Macao Featured Products Zone” focused on prevention and healthy living. Health policy meets global tech: A Hong Kong–Macau–linked FCC move drew attention for shifting from blocking products to targeting rules around testing and telecom operations.